Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics.
Bourner J. et al, (2025), Emerging infectious diseases, 31, 9 - 16
Improving clinical care of patients in Nipah outbreaks: moving beyond 'compassionate use'.
Hassan MZ. et al, (2025), The Lancet regional health. Southeast Asia, 33
Clinical characterisation and outcomes of human clade IIb mpox virus disease - a European multicentre observational cohort study (MOSAIC).
Pesonel E. et al, (2025), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
The priority review voucher: a misconceived quid pro quo.
Olliaro P. and Torreele E., (2024), BMJ Glob Health, 9
Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials
Chan XHS. et al, (2024), The Lancet Microbe, 101002 - 101002
Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa.
van Dorst PWM. et al, (2024), Applied health economics and health policy, 22, 701 - 715
Impact of a package of point-of-care diagnostic tests, a clinical diagnostic algorithm and adherence training on antibiotic prescriptions for the management of non-severe acute febrile illness in primary health facilities during the COVID-19 pandemic in Burkina Faso.
Kiemde F. et al, (2024), BMC infectious diseases, 24
An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus an aminoglycoside + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial-an update to the published protocol.
Randremanana RV. et al, (2024), Trials, 25
At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods.
Mesinovic M. et al, (2024), Scientific reports, 14
Challenges in clinical diagnosis of Clade I Mpox: Highlighting the need for enhanced diagnostic approaches.
Bourner J. et al, (2024), PLoS neglected tropical diseases, 18
Interpretations of Studies on SARS-CoV-2 Vaccination and Post-acute COVID-19 Sequelae.
Gonçalves BP. et al, (2024), Epidemiology (Cambridge, Mass.), 35, 368 - 371
The facilitators of and barriers to antimicrobial use and misuse in Lalitpur, Nepal: a qualitative study.
Udas S. et al, (2024), BMC public health, 24
Diagnostic tests for human Schistosoma mansoni and Schistosoma haematobium infection: a systematic review and meta-analysis.
Vaillant MT. et al, (2024), The Lancet. Microbe
Systematic Review of Scales for Measuring Infectious Disease–Related Stigma
Paterson A. et al, (2024), Emerging Infectious Diseases, 30
Involving patients in drug development for Neglected Tropical Diseases (NTDs): A qualitative study exploring and incorporating preferences of patients with cutaneous leishmaniasis into Target Product Profile development.
Castro MDM. et al, (2024), PLoS neglected tropical diseases, 18
Expanded Access Programme for the use of tecovirimat for the treatment of monkeypox infection: A study protocol for an Expanded Access Programme.
Bourner J. et al, (2024), PloS one, 19
Experiences and challenges with the new European Clinical Trials Regulation.
Patrick-Brown TDJH. et al, (2024), Trials, 25
Bubonic plague: can the size of buboes be accurately and consistently measured with a digital calliper?
Bourner J. et al, (2023), Trials, 24
Implementation of Recommendations on the Use of Corticosteroids in Severe COVID-19.
Camirand-Lemyre F. et al, (2023), JAMA network open, 6
Variability in clinical assessment of clade IIb mpox lesions
Jones B. et al, (2023), International Journal of Infectious Diseases, 137, 60 - 62
Major adverse cardiovascular events (MACE) in patients with severe COVID-19 registered in the ISARIC WHO clinical characterization protocol: A prospective, multinational, observational study.
Reyes LF. et al, (2023), Journal of critical care, 77
Laboratory Diagnosis of Mpox, Central African Republic, 2016-2022.
Garba-Ouangole S. et al, (2023), Emerging infectious diseases, 29, 1846 - 1849
A Randomized Trial to Assess the Impact of a Package of Diagnostic Tools and Diagnostic Algorithm on Antibiotic Prescriptions for the Management of Febrile Illnesses Among Children and Adolescents in Primary Health Facilities in Burkina Faso
Kiemde F. et al, (2023), Clinical Infectious Diseases, 77, S134 - S144
Impact of Point-of-Care Rapid Diagnostic Tests on Antibiotic Prescription Among Patients Aged <18 Years in Primary Healthcare Settings in 2 Peri-Urban Districts in Ghana: Randomized Controlled Trial Results
Adjei A. et al, (2023), Clinical Infectious Diseases, 77, S145 - S155
Impact of the Introduction of a Package of Diagnostic Tools, Diagnostic Algorithm, and Training and Communication on Outpatient Acute Fever Case Management at 3 Diverse Sites in Uganda: Results of a Randomized Controlled Trial
Kapisi J. et al, (2023), Clinical Infectious Diseases, 77, S156 - S170
A Qualitative Assessment of a Training and Communication Intervention on Antibiotic Prescription Practices Among Health Workers and Outpatients at Public Health Facilities in Uganda.
Kaawa-Mafigiri D. et al, (2023), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 77, S191 - S198
Breakthrough treatments for Ebola virus disease, but no access-what went wrong, and how can we do better?
Torreele E. et al, (2023), The Lancet. Infectious diseases, 23, e253 - e258
Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry.
Griffee MJ. et al, (2023), Research and practice in thrombosis and haemostasis, 7
Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19.
Wainstein M. et al, (2023), Kidney international reports
On the importance and challenges of global access to proven life-saving treatments for Ebolavirus - Authors' reply.
Torreele E. et al, (2023), The Lancet. Infectious diseases, 23, 407 - 408
The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
Farlow A. et al, (2023), Vaccines (Basel), 11
[MOSAIC: a European cohort study of human Mpox - the challenges of clinical research in outbreaks].
Kali S. et al, (2023), Virologie (Montrouge, France), 27, 23 - 26
Malaria patient spectrum representation in therapeutic clinical trials of uncomplicated malaria: a scoping review of the literature.
Arena L. et al, (2023), Malaria journal, 22
MOSAIC: a European cohort study of human Mpox - the challenges of clinical research in outbreaks.
Kali S. et al, (2023), Virologie (Montrouge, France), 27, 12 - 15
A legacy of progress in clinical pharmacology and social justice; remembering Peter Ian Folb.
Barnes KI. et al, (2023), Bulletin of the World Health Organization, 101, 3 - 3A
Involving patients in drug development for neglected tropical diseases (NTDs): A qualitative study exploring and incorporating preferences of patients with cutaneous leishmaniasis into target product profile development
Erber A. et al, (2023), TROPICAL MEDICINE & INTERNATIONAL HEALTH, 28, 387 - 387
Studying the post-COVID-19 condition: research challenges, strategies, and importance of Core Outcome Set development
Munblit D. et al, (2022), BMC Medicine, 20
Tecovirimat for Monkeypox in Central African Republic under Expanded Access.
Mbrenga F. et al, (2022), The New England journal of medicine, 387, 2294 - 2295
Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis
Dahal P. et al, (2022), Malaria Journal, 21
Symptom‐based case definitions for COVID‐19: Time and geographical variations for detection at hospital admission among 260,000 patients
Baruch J. et al, (2022), Influenza and Other Respiratory Viruses, 16, 1040 - 1050
Paediatric COVID-19 mortality: a database analysis of the impact of health resource disparity.
Marwali EM. et al, (2022), BMJ paediatrics open, 6
Monkeypox: how will we know if the treatments work?
Rojek A. et al, (2022), The Lancet. Infectious diseases, 22, 1269 - 1270
Characterising Long Covid: a living systematic review update with controlled studies
Michelen M. et al, (2022)